<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Immunology Product Guide &#187; influenza vaccine</title>
	<atom:link href="http://www.immunologyproductguide.com/blog/tag/influenza-vaccine/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.immunologyproductguide.com/blog</link>
	<description>A comprehensive guide to immunology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 10:09:04 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Vical Advocates DNA Vaccine Approach With Pandemic Influenza Experts</title>
		<link>http://www.immunologyproductguide.com/blog/2009/12/16/vical-advocates-dna-vaccine-approach-with-pandemic-influenza-experts/</link>
		<comments>http://www.immunologyproductguide.com/blog/2009/12/16/vical-advocates-dna-vaccine-approach-with-pandemic-influenza-experts/#comments</comments>
		<pubDate>Wed, 16 Dec 2009 11:32:58 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Vaccination]]></category>
		<category><![CDATA[influenza]]></category>
		<category><![CDATA[DNA vaccine technology]]></category>
		<category><![CDATA[influenza vaccine]]></category>
		<category><![CDATA[Vaxfectin(R) adjuvant]]></category>
		<category><![CDATA[Vical Incorporated]]></category>

		<guid isPermaLink="false">http://www.immunologyproductguide.com/blog/?p=201</guid>
		<description><![CDATA[Vical Incorporated has announced that the company addressed an international gathering of pandemic influenza vaccine experts and potential commercial partners to encourage broader use of the company&#8217;s DNA vaccine technology and Vaxfectin(R) adjuvant. DNA vaccines can be developed and produced very quickly using scaleable manufacturing processes which are not dependent upon chicken eggs or other [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.immunologyproductguide.com/blog/wp-content/uploads/2009/12/Vical-Advocates.png"><img class="alignleft size-full wp-image-202" style="margin: 5px" src="http://www.immunologyproductguide.com/blog/wp-content/uploads/2009/12/Vical-Advocates.png" border="0" alt="Vical Advocates" width="200" height="81" /></a>Vical Incorporated has announced that the company addressed an international gathering of pandemic influenza vaccine experts and potential commercial partners to encourage broader use of the company&#8217;s DNA vaccine technology and Vaxfectin(R) adjuvant. DNA vaccines can be developed and produced very quickly using scaleable manufacturing processes which are not dependent upon chicken eggs or other cell culture methods.</p>
<p>For the full story, <a href="http://money.cnn.com/news/newsfeeds/articles/globenewswire/179914.htm" target="_blank">Click Here</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.immunologyproductguide.com/blog/2009/12/16/vical-advocates-dna-vaccine-approach-with-pandemic-influenza-experts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis starts earlier Fluvirin shipment</title>
		<link>http://www.immunologyproductguide.com/blog/2009/08/06/novartis-starts-earlier-fluvirin-shipment/</link>
		<comments>http://www.immunologyproductguide.com/blog/2009/08/06/novartis-starts-earlier-fluvirin-shipment/#comments</comments>
		<pubDate>Thu, 06 Aug 2009 11:51:37 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Vaccination]]></category>
		<category><![CDATA[influenza]]></category>
		<category><![CDATA[Fluvirin]]></category>
		<category><![CDATA[H1N1 swine flu]]></category>
		<category><![CDATA[influenza vaccine]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pre-pandemic influenza vaccine]]></category>

		<guid isPermaLink="false">http://www.immunologyproductguide.com/blog/?p=117</guid>
		<description><![CDATA[Novartis Vaccines has started shipping the first of 30 million doses of its Fluvirin® seasonal influenza vaccine to the US. The shipping has started weeks ahead of schedule. The vaccine indicated for patients aged four years and over will be used to help meet the anticipated increase in demand for the seasonal vaccine as a [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.immunologyproductguide.com/blog/wp-content/uploads/2009/08/Novartis.png"><img class="alignleft size-full wp-image-119" style="margin: 5px" src="http://www.immunologyproductguide.com/blog/wp-content/uploads/2009/08/Novartis.png" alt="Novartis" width="200" height="55" /></a>Novartis Vaccines has started shipping the first of 30 million doses of its Fluvirin® seasonal influenza vaccine to the US. The shipping has started weeks ahead of schedule. The vaccine indicated for patients aged four years and over will be used to help meet the anticipated increase in demand for the seasonal vaccine as a result of the current global (A) H1N1 swine flu pandemic.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.immunologyproductguide.com/blog/2009/08/06/novartis-starts-earlier-fluvirin-shipment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
